ArticleERJ open research2025
Late pulmonary adverse effects in childhood and adolescent acute lymphoblastic leukaemia survivors: a cross-sectional ALL-STAR Lungs study.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prevalence of respiratory complications in long-term survivors of childhood and adolescent cancer: a systematic review and meta-analysis.Translational pediatrics · 2026Article
- Pulmonary Function Deficit and Clinical Associations in Childhood Acute Lymphoblastic Leukaemia Survivors: A National Retrospective ALL-STAR Lungs Cohort Study.Pediatric pulmonology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Childhood acute lymphoblastic leukaemia (ALL) survival rates have improved, reaching 95%. However, 25-50% of survivors experience significant treatment-related toxicities. This study investigated late pulmonary adverse effects, including pulmonary symptoms and pulmonary function, in childhood ALL survivors compared to controls. Methods: This Danish national cross-sectional study (February 2019 to May 2024) recruited ALL survivors (n=295 eligible) and matched controls 1:1 for pulmonary symptom questionnaire and pulmonary function tests (PFTs): nitrogen multiple breath washout, spirometry, impulse oscillometry, bronchodilator response, diffusing capacity of the lung for carbon monoxide ( Results: Among 192 survivors and 213 controls performing PFTs, 185 survivors and 209 controls had valid PFTs included in analyses. Prevalences of resting and exertional dyspnoea in survivors (2% and 14%, respectively) Conclusions: We found a higher reported prevalence of exertional dyspnoea and impaired pulmonary function in HR and HR-SCT survivors compared to controls. Reassuringly, non-HR/HR-SCT survivors demonstrated pulmonary function comparable to peers. The findings highlight the need for timely detection and tailored monitoring of pulmonary function deficit to improve pulmonary health in HR and HR-SCT survivors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.